SPRAVATO® (esketamine) is the first and only NMDA receptor antagonist approved for 2 subtypes of MDD in adult patients1
SPRAVATO® hypothesized mechanism of action (MOA)
TRD=treatment-resistant depression in adults.
MDSI=depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
UNMET NEED IN TRD
Even after multiple treatment steps, patients with TRD may continue to experience symptoms of MDD including2*:
• Depressed mood
• Loss of interest or pleasure
• Change in sleep, appetite, or weight
• Diminished concentration
• Feelings of worthlessness and guilt
• Psychomotor agitation or retardation
• Suicidal ideation
• Fatigue or loss of energy
In the STAR*D trial3
• About one-third of patients with MDD did not respond to ≥2 oral ADs and may be considered to have TRD
• By the third line of oral therapy, remission rates dropped below 15%
SPRAVATO® clinical program overview
Studied in more than 1700 adult patients with treatment-resistant depression across all studies1
BASELINE PATIENT CHARACTERISTICS
DID NOT RESPOND TO ≥2 and ≤5 ORAL ANTIDEPRESSANTS (ADs)
• Adults with major depressive disorder (MDD) who had not responded adequately in the current depressive episode to ≥2 and ≤5 different ADs of adequate dose and duration1,4
MODERATELY TO SEVERELY DEPRESSED
• Patients included those with moderate to severe depression, based on MADRS scores1
COMPARED TO PLACEBO NASAL SPRAY + ORAL AD1
MADRS=Montgomery-Åsberg Depression Rating Scale.
*DSM-5 criteria for major depressive disorder.
Meet 3 adult patients with TRD who may be appropriate for SPRAVATO® therapy*
SPRAVATO® therapy for appropriate adult patients with TRD should only begin after a full evaluation and discussion with a healthcare provider.
*Not actual patients.
To hear stories from real patients with TRD who were treated with SPRAVATO® visit www.spravato.com/trd/patient-stories.
1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.
2. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2010:1-152.
3. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
4. Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study [published online May 21, 2019]. Am J Psychiatry. 2019;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172